Last 45 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.06 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.08 | 2.17 | 1.10 | 1.34 | 0.82 | 3.02 | 4.67 | 3.54 | 3.48 | 0.97 | 0.85 | 0.93 | 0.39 | 0.87 | 1.13 | 3.08 | 3.01 | 5.13 | 7.56 | 13.06 | 17.99 |
| — | -28.3% | -76.5% | -62.2% | -76.4% | +212.0% | +450.1% | +282.2% | +782.7% | +11.9% | -25.2% | -69.9% | -86.9% | -83.1% | -85.0% | -76.4% | -83.3% | -51.8% | -68.0% | -11.7% | -67.4% | |
| P/B Ratio | 1.25 | — | — | — | 23.69 | 6.80 | 8.24 | 3.12 | 3.96 | 0.68 | 0.62 | 0.50 | 0.36 | 0.43 | 0.43 | 1.13 | 1.02 | 1.52 | 1.84 | 2.45 | 3.35 |
| — | — | — | — | +497.5% | +901.9% | +1230.3% | +528.0% | +1001.4% | +59.7% | +42.7% | -56.1% | -64.8% | -72.0% | -76.5% | -53.8% | -69.5% | -5.0% | -38.3% | +11.0% | +5.9% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 39.1% | 23.0% | 49.3% | 58.0% | 24.2% | 51.9% | 51.9% | 53.0% | 59.0% | 58.7% | 59.4% | 59.5% | 72.0% | 58.4% | 58.6% | 58.5% | 58.5% | 57.9% | 58.4% | 58.9% | 59.5% |
| — | -55.8% | -5.1% | +9.5% | -59.1% | -11.6% | -12.6% | -11.0% | -18.0% | +0.5% | +1.4% | +1.7% | +23.1% | +0.9% | +0.4% | -0.6% | -1.7% | +1.7% | +912.3% | +928.6% | +1303.4% | |
| Operating Margin | -138.8% | -347.2% | -266.5% | -166.3% | -96.7% | -108.6% | -220.9% | -270.4% | -68.9% | -57.6% | -81.9% | -86.4% | -82.8% | -56.0% | -74.5% | -76.8% | -120.6% | -85.0% | -111.4% | -271.9% | -315.4% |
| — | -219.7% | -20.6% | +38.5% | -40.4% | -88.4% | -169.8% | -212.9% | +16.9% | -3.0% | -9.8% | -12.6% | +31.3% | +34.1% | +33.1% | +71.8% | +61.7% | +80.7% | +66.5% | -5.6% | +65.2% | |
| Net Margin | -137.6% | -353.9% | -320.4% | -172.3% | -107.6% | -107.7% | -175.0% | -279.5% | -88.1% | -52.4% | -104.3% | -72.0% | -128.0% | -50.9% | -89.6% | -94.9% | -61.2% | -126.0% | -97.0% | -242.0% | -294.5% |
| — | -228.5% | -83.0% | +38.4% | -22.1% | -105.4% | -67.9% | -288.2% | +31.2% | -3.0% | -16.4% | +24.1% | -109.3% | +59.6% | +7.6% | +60.8% | +79.2% | +68.5% | +70.2% | +2.3% | +69.3% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -301.8% | — | — | — | -183.1% | -73.4% | -56.9% | -48.1% | -16.2% | -8.9% | -17.6% | -9.3% | -26.0% | -6.0% | -8.2% | -8.3% | -5.2% | -9.0% | -5.8% | -12.3% | -13.1% |
| — | — | — | — | -1027.8% | -725.9% | -222.4% | -416.7% | +37.6% | -47.7% | -116.3% | -11.9% | -405.2% | +33.2% | -40.7% | +32.4% | +60.8% | +47.6% | +41.5% | -34.7% | +1.1% | |
| ROA | -60.9% | -39.1% | -37.1% | -22.8% | -24.5% | -14.6% | -12.7% | -14.3% | -8.1% | -6.1% | -12.3% | -6.5% | -17.4% | -4.2% | -6.2% | -6.4% | -4.1% | -7.3% | -4.7% | -10.1% | -10.8% |
| — | -167.6% | -191.4% | -59.1% | -202.5% | -139.8% | -3.5% | -119.7% | +53.5% | -44.6% | -99.2% | -1.4% | -327.3% | +42.1% | -30.2% | +36.2% | +62.4% | +51.5% | +47.8% | -20.5% | +11.0% | |
| ROIC | -153.0% | — | — | -154.9% | -71.9% | -36.9% | -33.1% | -27.6% | -12.1% | -11.3% | -14.6% | -16.2% | -23.1% | -6.4% | -6.6% | -7.2% | -12.4% | -8.5% | -9.9% | -21.5% | -25.3% |
| — | — | — | -462.1% | -494.9% | -225.6% | -126.8% | -70.2% | +47.6% | -78.1% | -120.9% | -125.0% | -86.1% | +24.7% | +33.0% | +66.5% | +50.9% | +75.3% | +41.4% | -31.1% | -12.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 11.96 | — | — | — | 11.96 | 1.38 | 2.05 | 1.20 | 0.88 | — | — | — | 0.02 | 0.05 | 0.03 | 0.02 | 0.04 | 0.03 | 0.04 | 0.04 | 0.03 |
| — | — | — | — | +1261.0% | — | — | — | +4277.1% | — | — | — | -50.0% | +60.7% | -22.6% | -54.8% | +30.0% | +62.6% | +120.5% | +447.0% | +31.3% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.09 | 0.30 | 0.48 | 0.81 | 1.09 | 3.20 | 3.88 | 5.05 | 3.55 | 4.91 | 5.12 | 4.74 | 4.32 | 1.87 | 3.21 | 3.80 | 4.70 | 7.23 | 8.33 | 8.93 | 9.28 |
| — | -90.6% | -87.6% | -84.0% | -69.4% | -34.9% | -24.2% | +6.5% | -17.8% | +162.9% | +59.6% | +24.9% | -8.1% | -74.1% | -61.5% | -57.5% | -49.4% | -51.8% | -37.6% | +12.6% | +19.9% | |
| Quick Ratio | 0.94 | 0.24 | 0.39 | 0.68 | 0.94 | 2.32 | 2.36 | 3.25 | 2.60 | 4.17 | 4.47 | 4.13 | 3.96 | 1.68 | 2.77 | 3.53 | 4.56 | 7.05 | 7.99 | 8.63 | 9.11 |
| — | -89.8% | -83.4% | -79.0% | -63.8% | -44.3% | -47.3% | -21.5% | -34.3% | +148.7% | +61.4% | +17.1% | -13.1% | -76.2% | -65.3% | -59.1% | -50.0% | -52.5% | -39.7% | +12.6% | +27.1% | |
| Interest Coverage | -42.71 | -54.81 | -44.91 | -53.57 | — | -132.54 | -173.71 | -48.02 | — | — | — | — | — | -488.77 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 45 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CASI stock.
CASI Pharmaceuticals, Inc.'s current P/E is -0.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
CASI Pharmaceuticals, Inc.'s current operating margin is -138.8%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking CASI Pharmaceuticals, Inc.'s business trajectory between earnings reports.